|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500096155 |
|
最近更新日期: Date of Last Refreshed on: |
2025-01-20 09:16:08 |
|
注册时间: Date of Registration: |
2025-01-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
腹腔感染致脓毒症患者的临床特征、诊治策略及预后:一项多中心前瞻性观察性队列研究 |
|
Public title: |
Clinical Characteristics, Diagnostic and Therapeutic Strategies and Prognosis of Patients with Sepsis Resulting from Intra-abdominal Infection: A Multicenter Observational Cohort Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
重症监护室腹腔感染致脓毒症患者的临床特征、诊治模式和结果:一项多中心观察性队列研究 |
|
Scientific title: |
Clinical Characteristics, Diagnostic and Therapeutic Strategies and Prognosis of Patients with Sepsis Resulting from Intra-abdominal Infection: A Multicenter Observational Cohort Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
姚志伟 |
研究负责人: |
吴骎 |
|
Applicant: |
Zhiwei Yao |
Study leader: |
Qin Wu |
|
申请注册联系人电话: Applicant telephone: |
+86 199 3455 0615 |
研究负责人电话: Study leader's telephone: |
+86 189 8060 5920 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
19934550615@163.com |
研究负责人电子邮件: Study leader's E-mail: |
qinwu@wchscu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国成都,四川大学华西医院重症医学科 |
研究负责人通讯地址: |
中国成都,四川大学华西医院重症医学科 |
|
Applicant address: |
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. |
Study leader's address: |
Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital of Sichuan University |
||
|
研究负责人所在单位: |
四川大学华西医院 |
||
|
Affiliation of the Leader: |
West China Hospital of Sichuan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024年审(1189)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川大学华西医院生物医学伦理审查委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Review Committee of West China Hospital, Sichuan University. |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-27 00:00:00 |
||
|
伦理委员会联系人: |
李娜 |
||
|
Contact Name of the ethic committee: |
Na Li |
||
|
伦理委员会联系地址: |
四川省成都市武侯区国学巷37号八角亭2105 |
||
|
Contact Address of the ethic committee: |
Room 2105, Bajiaoting Building, No. 37,Guoxue Alley, Wuhou District, Chengdu City, Sichuan Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8542 2654 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University. |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国四川省成都市武侯区国学巷37 号 邮编:610041 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37th Guoxue Ln, Wuhou Zone, 610041 chengdu, sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川大学华西医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
West China hospital |
||||||||||||||||||||||
|
Target disease: |
Sepsis Related to Intra-abdominal Infection |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
通过本研究,我们预计识别关键早期预警指标和新的生物标志物组合,评估不同治疗策略的效果,优化个体化治疗方案,开发专门的预后评分系统。本研究将为提高腹腔感染致脓毒症的诊治水平提供坚实的科学基础,有助于规范诊疗流程,提高早期识别和干预能力,降低病死率,改善长期预后,具有重大的临床价值和公共卫生意义。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to identify key early warning indicators and novel biomarker combinations, evaluate the efficacy of different therapeutic strategies, optimize individualized treatment regimens, and develop a dedicated prognostic scoring system. The findings will provide robust scientific evidence to enhance the diagnosis and treatment of sepsis caused by intra-abdominal infection, contribute to the standardization of clinical workflows, strengthen early recognition and intervention capabilities, reduce mortality rates, improve long-term outcomes, and yield significant clinical and public health benefits. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄:18 岁—90 岁 2.入院 24 小时内诊断为 IAIs 并发脓毒症 3.患者或其法定代理人同意与研究并签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age from 18 to 90 years old 2.Diagnosed with IAIs complicated by sepsis within 24 hours of admission. 3.The patient or their legal representative agrees to participate in the study and signs the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.确诊腹腔感染时间为患者入ICU 24h 2.预期存活时间小于24h 3.预期ICU住院时间小于24h 4.入ICU后姑息治疗 5.孕妇或产妇 6.患者已经参与过其他的干预性临床研究 7.该患者已经纳入过本研究,此次为转出后转入 8.患者从其他医院转院,且在前一家医院ICU住院时间超过7天; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The time of confirmed intra-abdominal infection is 24 hours after the patient's admission to the ICU. 2. The expected survival time is less than 24 hours. 3. The expected length of stay in the ICU is less than 24 hours. 4. Palliative treatment after admission to the ICU. 5. Pregnant women or parturients. 6. The patient has already participated in other interventional clinical studies. 7. This patient has already been included in this study and is transferred in after being transferred out. 8. The patient is transferred from another hospital and has stayed in the ICU of the previous hospital for more than 7 days. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-01 00:00:00至 To 2026-02-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-02-01 00:00:00 至 To 2025-08-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
None |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
在每个参与中心,将指定符合研究资格标准的临床医生负责数据收集和记录。这些临床医生的资格认定流程将在所有中心标准化,以确保数据收集的一致性和可靠性。指定的临床医生将是具有临床研究相关经验和培训的 ICU 医生。 为便于高效、准确地收集数据,将开发一个全面的电子病例报告表(eCRF),并托管在安全的基于网络的平台上。eCRF 将被设计为捕获研究方案中概述的所有所需数据元素,包括患者人口统计学信息、临床特征、治疗细节和结局。 指定的临床医生将从各自中心使用的电子病历系统或其他相关电子医疗护理系统中获取必要数据。为确保数据质量并尽量减少转录错误,eCRF 将纳入数据验证检查和逻辑约束,提示临床医生审查并纠正任何差异或缺失数据。 将通过独特的安全登录系统提供对 eCRF 的访问。为简化登录流程并提升用户体验,eCRF 平台将支持基于二维码的身份验证。指定的临床医生只需使用移动设备扫描二维码即可安全登录并输入数据,减少手动输入登录凭据的需求。 在研究开始前,将对 eCRF 系统进行全面测试和验证,以确保其功能、可靠性,并符合数据保护法规。研究团队将为指定的临床医生提供 eCRF 使用和数据输入程序的培训和支持,以促进所有参与中心的数据质量和一致性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
At each participating center, a designated clinician who meets the study's qualification criteria will be responsible for data collection and recording. The qualification process for these clinicians will be standardized across all centers to ensure consistency and reliability of data collection. The designated clinicians will be ICU physicians with relevant experience and training in clinical research. To facilitate efficient and accurate data collection, a comprehensive electronic case report form (eCRF) will be developed and hosted on a secure, web-based platform. The eCRF will be designed to capture all required data elements as outlined in the study protocol, including patient demographics, clinical characteristics, treatment details, and outcomes. The designated clinicians will obtain the necessary data from the electronic medical record system or other relevant electronic medical care systems utilized by their respective centers. To ensure data quality and minimize transcription errors, the eCRF will incorporate data validation checks and logical constraints, prompting the clinicians to review and correct any discrepancies or missing data. Access to the eCRF will be provided through a unique, secure login system. To streamline the login process and enhance user experience, the eCRF platform will support QR code-based authentication. The designated clinicians can simply scan the QR code using their mobile devices to securely log in and enter data, reducing the need for manual entry of login credentials. The eCRF system will be thoroughly tested and validated prior to study commencement to ensure its functionality, reliability, and compliance with data protection regulations. The study team will provide training and support to the designated clinicians on the use of the eCRF and the data entry procedures to promote data quality and consistency across all participating centers. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |